Icon PLC (ICLR)
ICON provides outsourced clinical development and commercialization services to pharmaceutical, biotech and medical device companies. It last closed at $195.02 on Nov 17, up 1.89% on the day. ICLR last reported earnings on Tue, Oct 27, 2026. The average 12-month price target from 7 analysts is $239.71 (+22.9% from the last close), with a high of $268.00 and a low of $215.00. Analyst consensus is Buy, based on the latest ratings from 7 firms (4 buy, 3 hold, 0 sell). In the past 30 days there were 4 dark pool prints totaling $5.0M, the largest $1.8M.
Key Stats
Last 12 monthsNot reported for this period.
From ICLR's SEC filings, latest 20-F for the period ending Sep 30, 2026 (filed May 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on ICLR in the past 90 days. The average target is $239.71, with a high of $268.00 and a low of $215.00, compared with the last close of $195.02.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | RBC Capital | Target raised | Buy | $185 → $226 |
| Oct 29 | Citigroup | Target raised | Hold | $175 → $215 |
| Oct 29 | TD Cowen | Target raised | Buy | $197 → $254 |
| Oct 29 | UBS | Target raised | Hold | $195 → $236 |
| Oct 29 | Barclays | Target raised | Hold | $175 → $230 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 25% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 53). The nearest support is the Pivot at $194.29, and the nearest resistance the Pivot R1 at $198.03.
| RSI (14) | 52.77 | Middle of its range | Neutral |
| MACD | 5.16 | Below its signal line | Bearish |
| Stochastic | 21.7 | Middle of its range | Neutral |
| ADX (14) | 35.2 | Trending up | |
| Williams %R | -78.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -31.5 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −4.3% | Change over 10 sessions | Bearish |
| ATR (14) | $8.15 | Typical daily range, 4.2% of price |
| RSI (14) | 61.91 | Strong, overbought above 70 | Neutral |
| MACD | 12.67 | Above its signal line | Bullish |
| Stochastic | 67.1 | Middle of its range | Neutral |
| ADX (14) | 31.5 | Trending up | |
| Williams %R | -38.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 116.3 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +15.2% | Change over 10 sessions | Bullish |
| ATR (14) | $17.41 | Typical daily range, 8.9% of price |
What happened before
See how ICLR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ICLR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.
Whale Options Flow
90DNo whale options trades in ICLR in the last 90 days.
Dark Pool
30DICLR Institutional Ownership
Full report →- ●198 buying vs 193 selling
- ▼Shares held by funds -5.2%
- ●Funds holding -4
- ▲Superinvestors: 3 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 422 | 426 | −0.9% |
| In funds' top 10 | 16 | 19 | −15.8% |
| Held by funds | – | – | – |
| New / increased | 45 / 153 | 83 / 147 | −13.9% |
| Reduced / sold out | 148 / 45 | 141 / 80 | −12.7% |
| Put/call ratio | 1.80 | 0.71 | +155.0% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ICLR is in one of them and how their past ICLR trades turned out.
ICLR News & Analysis
All StreetAlpha news →ICLR Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Kevin HernR · OK | Sell (partial) | $15K – $50K | Aug 14, 2026 | Sep 1, 2026 | 18 d |
| Donald J TrumpExecutive branch | Sell | $1K – $15K | Feb 19, 2026 | May 14, 2026 | 84 d |
| Kevin HernR · OK | Sell | $100K – $250K | Mar 5, 2026 | Apr 3, 2026 | 29 d |
| Julia LetlowR · LA | Sell | $1K – $15K | Feb 12, 2026 | Mar 12, 2026 | 28 d |
| Stephen I MiranExecutive branch | Sell | $15K – $50K | Jun 9, 2025 | Sep 6, 2025 | 89 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Icon
ICON is an outsourced development and commercialization services provider based in Dublin, Ireland. It serves pharmaceutical, biotechnology, medical device, and government and public health organizations. Its services cover clinical development strategy, trial design, full study execution and commercialization of treatments. The company works across all phases of clinical development, from Phase I to Phase IV studies. Offerings also include clinical trial management, consulting, contract staffing, data solutions and laboratory services.
- Headquarters
- Dublin 18, Ireland









